David Burns
Overview
Explore the profile of David Burns including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
5623
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Esteve J, Nagler A, Labopin M, Versluis J, Sanz J, Gedde-Dahl T, et al.
Am J Hematol
. 2025 Mar;
PMID: 40062532
Patients (pts) with myelodysplasia-related AML (MR-AML) are now genetically recategorized, with three different groups in the International Consensus Classification: AML with mutated TP53 (TP53-AML), with myelodysplasia-related gene mutations (MR-GM AML),...
2.
Burns D, Abbas A, Dasari S, Prabhakar P, Hebert-Davies J
J Orthop Trauma
. 2025 Feb;
39(3):153.
PMID: 39950823
No abstract available.
3.
Burns D, LoPolito A, Hoellwarth J, Reif T, Fragomen A, Rozbruch S
J Am Acad Orthop Surg Glob Res Rev
. 2025 Feb;
9(2).
PMID: 39899739
Background: Limb length discrepancy (LLD) after total hip arthroplasty (THA) is a common occurrence and can lead to back pain, disordered gait, and decreased functional outcomes. Femoral lengthening ipsilateral to...
4.
Boyer P, Burns D, Razmjou H, Renteria C, Sheth U, Richards R, et al.
J Am Acad Orthop Surg
. 2025 Jan;
PMID: 39888607
Introduction: Exercise-based physiotherapy is an established treatment of rotator cuff injury. Objective assessment of at-home exercise is critical to understand its relationship with clinical outcomes. This study uses the Smart...
5.
Lederman O, Moors-Mailei A, Peacock Y, McKeon G, Llana A, Burns D, et al.
Health Promot Int
. 2025 Jan;
40(1).
PMID: 39835581
Pasifika communities in Western Sydney experience significant health disparities, particularly related to chronic diseases such as cardiovascular conditions and diabetes. Physical activity is known to improve both physical and mental...
6.
Dragoi D, Cusworth S, Oldham L, Sanderson R, Norman J, Chandan J, et al.
Br J Haematol
. 2025 Jan;
PMID: 39821591
Data on the impact of ethnic and socioeconomic factors on Chimeric antigen receptor (CAR) T-cell therapy (access and outcomes are limited, but key to understand whether results from the registration...
7.
Barrett A, Shah N, Chadwick A, Burns D, Burton C, Cutter D, et al.
Br J Haematol
. 2024 Nov;
206(1):74-85.
PMID: 39506502
This good practice paper (GPP) is intended to support clinicians in assessing patient fitness for bleomycin and in management of bleomycin pulmonary toxicity (BPT) where it occurs. Bleomycin, originally developed...
8.
Burns D, Abbas A, Dasari S, Prabhakar P, Hebert-Davies J
J Orthop Trauma
. 2024 Oct;
38(11S):S8-S14.
PMID: 39431809
Objectives: To identify characteristics that contribute to surgical complexity in pilon fractures and to develop a machine learning (ML) Pilon Surgical Difficulty Score (PSDS) based on these factors. Methods: Design:...
9.
Khatsuria F, McMullan C, Aiyegbusi O, Shaw K, Iqbal R, Kinsella F, et al.
Lancet Oncol
. 2024 Oct;
25(10):e476-e488.
PMID: 39362259
Chimeric antigen receptor (CAR) T-cell therapy is associated with potentially severe toxicities that create a substantial burden for patients. Patient-reported outcomes (PROs) offer valuable insights into symptoms, functioning, and other...
10.
Masand N, Perry T, Pugh M, Fennell E, Hennessy A, Wei W, et al.
Haematologica
. 2024 Sep;
110(1):193-199.
PMID: 39219456
No abstract available.